Sunho Biologics Inc (2898.HK)

- (-) As of 06:07AM HKT. Market open.

Sunho Biologics Inc

Building 3
Room 302 No. 198 Peninsula Middle Road, Dipu Street Anji County
Huzhou
China

https://www.sunho-bio.com.cn

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Feng Zhang	Executive Chairman	N/A	N/A	1973
Dr. Liusong Yin	CEO, Chief Scientific Officer & Executive Director	N/A	N/A	1987
Ms. Chunqin Xu	CFO & Joint Company Secretary	N/A	N/A	1979
Ms. Xiaoling Jiang	VP & Executive Director	N/A	N/A	1982
Ms. Hoi Ting Wong	Joint Company Secretary	N/A	N/A	1989

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in .

Description

Sunho Biologics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics that regulate immune microenvironment by modulating the innate and adaptive immune systems. It offers IAH0968, an antibody-dependent cell mediated cytotoxicity enhanced monoclonal antibody, which is in the Phase II clinical trials for biliary tract carcinoma and colorectal cancer (CRC). The company also provides IAP0971 and IAE0972 immunocytokines, which have completed Phase I clinical trials for advanced solid tumors, including non-small cell lung cancer and CRC. In addition, its preclinical stage products include IBB0979, an immunocytokine for solid tumors; IBC0966, a clinical stage anti-PD-L1 antibody-signal regulatory protein bifunctional fusion protein for tumor specific immune responses; IBD0333 for tumor cells; IAN0982 for oncology; and ISH0988 and ISH0613 immunosuppressors focused on autoimmune diseases. The company was founded in 2018 and is headquartered in Huzhou, China. Sunho Biologics, Inc. is a subsidiary of Sunho Wisdom Investments Limited.

Corporate governance

Sunho Biologics Inc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.